Financial Performance - The company achieved total operating revenue of ¥415,674,365.78, representing a year-on-year increase of 1.87%[4] - Net profit attributable to shareholders decreased to ¥87,267,276.45, down 14.71% compared to the previous year[4] - The basic earnings per share fell to ¥0.60, a decline of 15.49% year-on-year[4] - Investment income decreased by approximately ¥6.6 million due to reduced profits from joint ventures[7] - The weighted average return on equity (after deducting non-recurring gains and losses) was 10.05%, down from 12.21% in the previous year[4] Assets and Equity - Total assets at the end of the reporting period reached ¥922,770,957.29, reflecting a growth of 5.08%[5] - The net assets attributable to shareholders increased to ¥783,254,611.97, up 4.90% year-on-year[5] Cost and Expenses - The decrease in net profit was primarily due to increased R&D expenses by approximately ¥4 million and higher management costs by about ¥1.6 million[7] - The company introduced new products such as Celecoxib capsules and Oseltamivir phosphate capsules, contributing to increased operational costs[7] Cautionary Note - The company emphasizes that the financial data presented is preliminary and subject to audit, urging investors to be cautious[9]
梓橦宫(832566) - 2024 Q4 - 年度业绩